IND filing of Medi4276, MedImmune’s first bispecific antibody-directed conjugate – a Biosuperior drug candidate with real potential to help certain types of breast cancer patients (2015) (Company Web Page, AstraZeneca, MAR 8, 2016, View Source [SID:1234509411]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!